Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

a 17.5% weight loss with semaglutide 2.4 mg. The safety profile of semaglutide 7.2 mg is similar to other GLP-1s. Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher ...

Study participants were randomly assigned to receive subcutaneous semaglutide 7.2mg, semaglutide 2.4mg, or placebo once weekly; all treatments were in conjunction with lifestyle interventions.

The company states: “Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating ...

The topline results from the ESSENCE trial of semaglutide showed that a once-weekly 2.4mg dose of the drug was better than placebo at resolving MASH and improving liver fibrosis, meeting its ...

The phase 3b STEP UP trial has been comparing the experimental 7.2mg dose of semaglutide to the standard 2.4mg dose of the drug and placebo, all given once weekly in conjunction with lifestyle ...

When applying the treatment policy estimand 2, people treated with semaglutide 7.2 mg achieved a superior weight loss of 18.7% compared to a reduction of 15.6% with semaglutide 2.4 mg and 3.9% ...